[go: up one dir, main page]

GT199800113A - Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. - Google Patents

Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.

Info

Publication number
GT199800113A
GT199800113A GT199800113A GT199800113A GT199800113A GT 199800113 A GT199800113 A GT 199800113A GT 199800113 A GT199800113 A GT 199800113A GT 199800113 A GT199800113 A GT 199800113A GT 199800113 A GT199800113 A GT 199800113A
Authority
GT
Guatemala
Prior art keywords
compound
pharmaceutical preparation
ulcer activity
oral pharmaceutical
procedure
Prior art date
Application number
GT199800113A
Other languages
English (en)
Inventor
Carlos Picornell Darder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8300432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT199800113(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT199800113A publication Critical patent/GT199800113A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PREPARACION FARMACEUTICA ORAL QUE COMPRENDE UN COMPUESTO DE ACTIVIDAD ANTIULCEROSA COMO PRINCIPIO ACTIVO, CARACTERIZADA POR EL HECHO DE QUE COMPRENDE: A) UN NUCLEO INERTE; B) UNA CAPA ACTIVA SOLUBLE O DE DESINTEGRACION RAPIDA EN AGUA OBTENIDA A PARTIR DE UNA UNICA SOLUCION SUSPENSION ACUOSA O HIDROALCOHOLICA QUE COMPRENDE: UN PRINCIPIO ACTIVO DE ACTIVIDAD ANTIULCEROSA DE FORMULA GENERAL (I), EN LA QUE A, R1 Y R2, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.
GT199800113A 1997-07-31 1998-07-27 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. GT199800113A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009701816A ES2137862B1 (es) 1997-07-31 1997-07-31 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.

Publications (1)

Publication Number Publication Date
GT199800113A true GT199800113A (es) 2000-01-18

Family

ID=8300432

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199800113A GT199800113A (es) 1997-07-31 1998-07-27 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.

Country Status (33)

Country Link
US (1) US20020098242A1 (es)
EP (1) EP1010423B1 (es)
JP (1) JP3961217B2 (es)
KR (1) KR100591488B1 (es)
AR (1) AR013242A1 (es)
AT (1) ATE317688T1 (es)
AU (1) AU751609B2 (es)
BG (1) BG64967B1 (es)
CA (1) CA2307037C (es)
CR (1) CR5826A (es)
CZ (1) CZ298700B6 (es)
DE (1) DE69833490T2 (es)
DK (1) DK1010423T3 (es)
ES (3) ES2137862B1 (es)
GT (1) GT199800113A (es)
HN (1) HN1998000113A (es)
HR (1) HRP20000053B1 (es)
HU (1) HU230635B1 (es)
IL (1) IL134158A (es)
MY (1) MY121353A (es)
NO (1) NO20000435L (es)
NZ (1) NZ502590A (es)
PA (1) PA8456401A1 (es)
PE (1) PE105199A1 (es)
PL (1) PL192961B1 (es)
PT (1) PT1010423E (es)
RU (1) RU2207114C2 (es)
SK (1) SK284892B6 (es)
TR (1) TR200000264T2 (es)
TW (1) TW533201B (es)
UA (1) UA66800C2 (es)
WO (1) WO1999006032A2 (es)
ZA (1) ZA986893B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
JP2004531467A (ja) 2000-11-28 2004-10-14 エフ エム シー コーポレーション 可食性pga被覆組成物
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
KR100447085B1 (ko) * 2001-11-08 2004-09-04 바램제약주식회사 마그네슘이온, 칼슘이온 또는 철이온이 고농도로 결합된알긴산의 제조 방법
IL161983A0 (en) * 2001-11-21 2005-11-20 Eisai Co Ltd Preparation compositions containing acid-unstable physiologically active compounds, and process for producing the same
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
ATE388695T1 (de) * 2002-08-02 2008-03-15 Ratiopharm Gmbh Pharmazeutische zusammensetzung enthaltend ein benzimidazol-derivat gemischt mit mikrokristalliner cellulose
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP1608347B1 (en) * 2003-03-28 2014-08-13 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
MY139427A (en) * 2004-03-26 2009-09-30 Eisai R&D Man Co Ltd Controlled-release pharmaceutical composition and method for producing the same
CA2555114C (en) 2004-03-31 2012-05-29 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006035417A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
BRPI0500586A (pt) * 2005-02-21 2006-10-10 Fundacao Oswaldo Cruz composição farmacêutica, processo para preparar dita composição, uso da respectiva composição no tratamento da imunodeficiência causada por infecção pelo hiv e respectivo método de tratamento
WO2006111980A2 (en) * 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1913138B1 (en) 2005-07-29 2016-08-24 Abbott Laboratories GmbH Processes for the manufacture of pancreatin powder with low virus content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
WO2008102264A2 (en) 2007-02-20 2008-08-28 Eurand Pharmaceuticals Limited Stable digestive enzyme compositions
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
US8951570B2 (en) * 2007-04-26 2015-02-10 Sigmoid Pharma Limited Manufacture of multiple minicapsules
EP2073798A2 (en) * 2007-05-01 2009-07-01 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
WO2009069280A1 (ja) * 2007-11-27 2009-06-04 Ohara Pharmaceutical Co., Ltd. 造粒物の製造法
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
ES2552723T3 (es) * 2008-05-06 2015-12-01 Dexcel Pharma Technologies Ltd. Formulación de bencimidazol estable
US8840934B2 (en) * 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
JP5911799B2 (ja) 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドSigmoid Pharma Limited ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
JP5309262B2 (ja) 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド フェキソフェナジン・マイクロカプセル及びそれを含む組成物
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
KR101968457B1 (ko) 2010-10-01 2019-04-11 앨러간 파마슈티컬스 인터내셔널 리미티드 장용 코팅된 저 강도 췌장 리파제 제제
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US20120328697A1 (en) * 2011-06-01 2012-12-27 Fmc Corporation Controlled Release Solid Dose Forms
WO2013010137A2 (en) * 2011-07-14 2013-01-17 Jacks Health Technologies Llc A composition, device and method for delayed and sustained release of brain energy molecules
US10953025B2 (en) * 2011-07-14 2021-03-23 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
MX351014B (es) 2011-08-08 2017-09-28 Aptalis Pharma Ltd Metodo para la prueba de disolucion de composiciones solidas que contienen enzimas digestivas.
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
JP2016537387A (ja) 2013-08-09 2016-12-01 アラガン ファーマシューティカルズ インターナショナル リミテッド 経腸投与に適した消化酵素組成物
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
MX2016016907A (es) 2014-06-19 2018-04-26 Aptalis Pharma Ltd Metodo para eliminar contaminantes virales de extractos pancreaticos.
MX2014008314A (es) * 2014-07-07 2016-01-06 Andres Abelino Choza Romero Procedimiento para mezclar sustancias, mediante nebulizacion.
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
SMT202100137T1 (it) 2014-11-07 2021-05-07 Sublimity Therapeutics Ltd Composizioni comprendenti la ciclosporina
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
ATE192932T1 (de) * 1993-09-09 2000-06-15 Takeda Chemical Industries Ltd Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
HUP0002524A2 (hu) 2001-08-28
KR20010022439A (ko) 2001-03-15
PA8456401A1 (es) 2000-09-29
US20020098242A1 (en) 2002-07-25
TR200000264T2 (tr) 2000-09-21
CZ2000344A3 (cs) 2000-06-14
HN1998000113A (es) 2000-01-06
KR100591488B1 (ko) 2006-06-22
ES2256943T3 (es) 2006-07-16
TW533201B (en) 2003-05-21
ZA986893B (en) 1999-01-27
CR5826A (es) 1998-09-28
UA66800C2 (uk) 2004-06-15
NO20000435L (no) 2000-03-23
DK1010423T3 (da) 2006-05-22
ES2137862A1 (es) 1999-12-16
WO1999006032A2 (es) 1999-02-11
DE69833490D1 (de) 2006-04-20
BG104193A (en) 2000-09-29
PT1010423E (pt) 2006-06-30
DE69833490T2 (de) 2006-10-19
NZ502590A (en) 2001-08-31
ATE317688T1 (de) 2006-03-15
PL338613A1 (en) 2000-11-06
BG64967B1 (bg) 2006-11-30
PL192961B1 (pl) 2006-12-29
ES2156699B1 (es) 2002-03-01
CA2307037A1 (en) 1999-02-11
HRP20000053A2 (en) 2000-08-31
ES2256943T4 (es) 2007-09-16
AU751609B2 (en) 2002-08-22
IL134158A0 (en) 2001-04-30
ES2137862B1 (es) 2000-09-16
RU2207114C2 (ru) 2003-06-27
SK1032000A3 (en) 2000-11-07
HUP0002524A3 (en) 2002-12-28
ES2156699A1 (es) 2001-07-01
IL134158A (en) 2004-08-31
AR013242A1 (es) 2000-12-13
EP1010423A2 (en) 2000-06-21
SK284892B6 (sk) 2006-02-02
PE105199A1 (es) 1999-11-19
MY121353A (en) 2006-01-28
HRP20000053B1 (en) 2003-10-31
EP1010423B1 (en) 2006-02-15
WO1999006032A3 (es) 1999-08-12
HU230635B1 (hu) 2017-05-29
JP3961217B2 (ja) 2007-08-22
CZ298700B6 (cs) 2007-12-27
JP2001511443A (ja) 2001-08-14
NO20000435D0 (no) 2000-01-27
CA2307037C (en) 2006-09-12
AU8217398A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
GT199800113A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
YU44404A (sh) Postupak za identifikovanje ciljnih enzima tumora
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
CY1110322T1 (el) Αναστολεις της her3 δραστικοτητας
GT200000002AA (es) Ureas difenilicias x-carboxiaril sustituidas como inhibidores de raf quinasa
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
PT1027037E (pt) Composicao farmaceutica que compreende clodronato como ingredientes activo e celulose microcristalina silicificada como excipiente
DE60312333D1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
DE69812343D1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
EP2116262A3 (en) Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
EP1291362A4 (en) COMPLEX OF FOLIC ACID AND POLYSACCHARIDES, THE PRODUCTION THEREOF AND THE COMPLEX COMPRISING THE COMPOSITION COMPRISING THE ACTIVE INGREDIENT COMPOSITION
JP2004518674A5 (es)
ATE420099T1 (de) Medikament zur wachstumsinhibierung von tumoren
IS5851A (is) Ný lyf til inntöku 5-HT4 gerandefna eða mótlyfja
EP1681290A3 (en) Imidazole derivatives, production method thereof and use thereof
Angeli et al. Activation studies with amines and amino acids of the α-carbonic anhydrase from the pathogenic protozoan Trypanosoma cruzi
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
JP3025817B2 (ja) 薬剤として用いられる発光物質及び高分子発光物質
BG104981A (en) Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
BR0307319A (pt) Forma de dosagem oral para liberação controlada de droga